The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 533-537

  Lehmann, David F ^a,b   Liu, Andrew ^b   Newman, Nancy ^a   Blair, Donald C ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG DETOXIFICATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; RACE DIFFERENCE;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; DRUG HYPERSENSITIVITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032801803     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schneider MM, Hoepelman AI, Schattenkerk JK, Nielsen TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs JC, et al: A controlled trial of aerosolized pentamidine or trimethoprimsulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-1841.
2. Medina I, Mills J, Leoung G, Nielsen TL, van der Graaf Y, Frissen JP: Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprimsulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-782.
3. van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW: Adverse reactions to cotrimoxazole in HIV infection. Lancet 1991;338:431-433.
4. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP: Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989;110:286-289.
5. Cribb AE, Miller M, Leeder S, Hill J, Spielberg SP: Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab Dispos 1991;19:900-906.
6. Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995;23:406-414.
7. Mitra AK, Kalhorn TF, Thummel KE, Unadkat JD, Slattery JT: Metabolism of arylamines by human liver microsomal cytochrome P-450 (abstract). International Society for the Study of Xenobiotics 1993;4:148.
8. Lee BL, Wong D, Benowitz NL, Sullam PM: Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-535.
9. deQuay B, Malinverni R, Lauterburg BH: Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 1992;6:815-819.
10. Lehmann DF, Holohan PD, Blair DC: Comparisons of oxidative metabolism and reductive capacity in sulfonamide-tolerant and -intolerant patients with human immunodeficiency virus. J Clin Pharmacol 1996;36:1149-1153.
11. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, LOSM, Krammer PH, Droge W, Lehmann V: HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO Journal 1995;14:546-554.
12. Lin KM, Poland RE, Wan YJ, Smith MW, Lesser IM: The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull 1996;32:205-217.
13. Slaughter RL, Edwards DJ: Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624.
14. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED. Unadkat JD, Slattery JT: Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 1996;59:332-340.
15. Lehmann DF, Newman N, Morse PD: The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol 1998;38:463-466.
16. Rieder MJ, Krause R, Bird IA, Dekaban GA: Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and non-infected cells. JAcquir Immune Defic Syndr Hum Retrovirol 1995;8:134-140.
17. Carr A, Swanson C, Penny R, Cooper DA: Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993;167:180-185.
18. Coopman SA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674.
19. DeHovitz JA, Johnson WD, Pape JW: Cutaneous reactions to trimethoprim-sulfamethoxazole in Haitians (letter). Ann Intern Med 1985;479-480.
20. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR: Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996;6:527-533.